KNSA · NASDAQ · Medical - Pharmaceuticals

Kiniksa Pharmaceuticals (KNSA)

Markets ARCALYST for recurrent pericarditis while advancing a cardiovascular-focused clinical pipeline.

$75.58
vs last close−2.42 (−3.10%)